Mannan-modified adenovirus as a vaccine to induce antitumor immunity

Gene Therapy

Volumn 14, Issue 8, 2007, Pages 657-663

  Ding, Z Y ^a   Wu, Y ^a   Luo, Y ^a   Su, J M ^a   Li, Q ^a   Zhang, X W ^a   Liu, J Y ^a   He, Q M ^a   Yang, L ^a   Tian, L ^a   Zhao, X ^a   Deng, H X ^a   Wen, Y J ^a   Li, J ^a   Kang, B ^a   Wei, Y Q ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; TELOMERASE REVERSE TRANSCRIPTASE; VIRUS VACCINE;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL MODEL; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENE EXPRESSION; IMMUNOMODULATION; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; T LYMPHOCYTE ACTIVATION;

ADENOVIRIDAE; ADOPTIVE TRANSFER; ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; GENE THERAPY; GENETIC ENGINEERING; LYMPHOCYTE DEPLETION; MANNANS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C;

ADENOVIRIDAE; MUS;

EID: 34247125248     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302893     Document Type: Article

References (40)

1. Boon TP, van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med 1996; 183: 725-729.
2. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001; 411: 380-384.
3. + T cells. Nat Med 2000; 6: 1154-1159.
4. Song W, Kong HL, Carpenter H, Torii H, Granstein R, Rafii S et al. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J Exp Med 1997; 186: 1247-1256.
5. Gong J, Chen L, Chen D, Kashiwaba M, Manome Y, Tanaka T et al. Induction of antigen-specific antitumor immunity with adenovirus-transduced dendritic cells. Gene Therapy 1997; 4: 1023-1028.
6. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011-2013.
7. Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddle SD et al. hEST, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 1997; 90: 785-795.
8. Vonderheide RH. Telomerase as a universal tumor-associated antigen for cancer immunotherapy. Oncogene 2002; 21: 674-679.
9. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 1999; 10: 673-679.
10. Heiser A, Maurice MA, Yancey DR, Wu NZ, Dahm P, Pruitt SK et al. Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. J Immunol 2001; 166 2953-2960.
11. Heiser A, Maurice MA, Yancey DR, Coleman DM, Dahm P, Vieweg J. Human dendritic cells transfected with renal tumor RNA stimulated polyclonal T-cell responses against antigens expressed by primary and metastatic tumors. Cancer Res 2001; 61: 3388-3393.
12. Nair SK, Heiser A, Boczkowski D, Majumdar A, Naoe M, Lebkowski JS et al. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med 2000; 6: 1011-1017.
13. Zhai Y, Yang JC, Kawakami Y, Spiess P, Wadsworth SC, Cardoza LM et al. Antigen-specific tumor vaccines development and characterization of recombinant adenoviruses encoding MART1 or gpl00 for cancer therapy. J Immunol 1996; 156: 700-710.
14. Toes RE, Hoeben RC, van der Voort EI, Ressing ME, van der Eb AJ, Melief CJ et al. Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion. Proc Natl Acad Sci USA 1997; 94: 14660-14665.
15. Miller G, Lahrs S, Pillarisetty VG, Shah AB, DeMatteo RP. Adenovirus infection enhances dendritic cell immunostimulatory properties and induces natural killer and T-cell-mediated tumor protection. Cancer Res 2002; 62: 5260-5266.
16. Korokhov N, Mikheeva G, Krendelshchikov A, Belousova N, Simonenko V, Krendelshchikova V et al. Targeting of adenovirus via genetic modification of the viral capsid combined with a protein bridge. J Virol 2003; 77: 12931-12940.
17. Wickham TJ, Segal DM, Roelvink PW, Carrion ME, Lizonova A, Lee GM et al. Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. J Virol 1996; 70 6831-6838.
18. Belousova N, Korokhov N, Krendelshchikova V, Simonenko V, Mikheeva G, Triozzi PL et al. Genetically targeted adenovirus vector directed to CD40-expressing cells. J Virol 2003; 77: 11367-11377.
19. Condaminet B, Peguet-Navarro J, Stahl PD, Dalbiez-Gauthier C, Schmitt D, Berthier-Vergnes O. Human epidermal Langerhans cells express the mannose-fucose binding receptor. Eur J Immunol 1998; 28: 3541-3551.
20. Apostolopoulos V, Pietersz GA, Ooveland BE, Sandrin MS, McKenzie IFC. Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses. Proc Natl Acad Sci USA 1995; 92: 10128-10132.
21. Milone MC, Fitzgerald-Bocarsly P. The Mannose receptor mediates induction of IFN-α in peripheral blood dendritic cells by enveloped RNA and DNA viruses. J Immunol 1998; 161: 2391-2399.
22. Gross DA, Graff-Dubois S, Opolon P, Cornet S, Alves P, Bennaceur-Griscelli A et al. High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. J Clin Invest 2004; 113: 425-433.
23. + T lymphocytes. Clin Cancer Res 2004; 1: 828-839.
24. + T cell responses in patients with metastatic prostate cancer. J Immunol 2005; 174: 3798-3807.
25. Carbone FR, Kurts C, Bennett SR, Miller JF, Heath WR. Cross-presentation: A general mechanism for CTL immunity and tolerance. Immunol Today 1998; 19: 368-373.
26. + T cells in the priming and effector/memory phases of adoptive immunotherapy. J Immunol 2000; 165: 4246-4253.
27. Murray JS. How the MHC selects Th1/Th2 immunity. Immunol Today 1998; 19: 157-163.
28. Romagnani S. The Th1/Th2 paradigm. Immunol Today 1997; 18: 263-266.
29. Chattergoon MA, Kim JJ, Yang JS, Robinson TM, Lee DJ, Dentchev T et al. Targeted antigen delivery to antigen-presenting cells including dendritic cells by engineered Fas-mediated apoptosis. Nat Biotechnol 2000; 18: 974-979.
30. Kumamoto T, Huang EK, Paek HJ, Morita A, Matsue H, Valentin RF et al. Induction of tumor-specific protective immunity by in situ Langerhans cell vaccine. Nat Biotechnol 2002; 20: 64-69.
31. Merad M, Sugie T, Engleman EG, Fong L. In vivo manipulation of dendritic cells to induce therapeutic immunity. Blood 2002; 99 1676-1682.
32. Watson M, Rudd PM, Bland M, Dwek RA, Axford JS. Sugar printing rheumatic diseases: A potential method for disease differentiation using immunoglobulin G oligosaccharides. Arthritis Rheum 1999; 42: 1682-1690.
33. Reitter JN, Means RE, Desrosiers RC. A role for carbohydrates in immune evasion in AIDS. Nat Med 1998; 4: 679-684.
34. Prowse KR, Greider CW. Developmental and tissue-specific regulation of mouse telomerase and telomere length. Proc Natl Acad Sci USA 1995; 92: 4818-4822.
35. Greenberg RA, Allsopp RC, Chin L, Morin GB, De RA. Expression of mouse telomerase reverse transcriptase during development, differentiation and proliferation. Oncogene 1998; 16: 1723-1730.
36. Martin-Rivera L, Herrera E, Albar JP, Blasco MA. Expression of mouse telomerase catalytic subunit in embryos and adult tissue. Proc Natl Acad Sci USA 1998; 95: 10471-10476.
37. He TC, Zhou S, Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998; 95: 2509-2514.
38. Hattori Y, Kawakami S, Lu Y, Nakamura K, Yamashita F, Hashida M. Enhanced DNA vaccine potency by mannosylated lipoplex after intraperitoneal administration. J Gene Med 2006; 8: 824-834.
39. Hattori Y, Kawakami S, Nakamura K, Yamashita F, Hashida M. Efficient gene transfer into macrophages and dendritic cells by in vivo gene delivery with mannosylated lipoplex via the intraperitoneal route. J Pharmacol Exp Ther 2006; 318: 828-834.
40. Lu Y, Wei YQ, Tian L, Zhao X, Yang L, Hu B et al. Immunogene therapy of tumors with vaccine based on xenogeneic epidermal growth factor receptor. J Immunol 2003; 170: 3162-3170.